What Edesa Biotech, Inc. does.

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our efforts on disease indications where there is compelling scientific rationale, no approved therapies or where there are unmet medical needs, and where there are large addressable market opportunities, among other factors. Our clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory.

In Medical Dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. CXCL10 has been shown to play a key role in the disease, and neutralization of CXCL10 has been demonstrated to both prevent and reverse depigmentation in animal models. To date, EB06 has demonstrated a favorable safety and tolerability profile. We have received regulatory approval from Health Canada to conduct a Phase 2 proof of concept study of EB06 in patients with moderate-to-severe nonsegmental vitiligo and we are in discussions with the U.S. Food and Drug Administration (“FDA”) for the same study. Subject to regulatory approval, we anticipate initiating enrollment by midyear 2026. Our Medical Dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (“ACD”), a common occupational skin condition. This asset is at the partnering stage.

Revenue and profit, by fiscal year.

More on EDSA.

• Edesa Biotech, Inc. summary
• Edesa Biotech, Inc. financial statements
• Edesa Biotech, Inc. key metrics
• Edesa Biotech, Inc. health scores and style box
• Edesa Biotech, Inc. earnings
• Edesa Biotech, Inc. dividends
• Edesa Biotech, Inc. valuation
• Edesa Biotech, Inc. ownership and insiders
• Edesa Biotech, Inc. peers

Figures from Edesa Biotech, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.